Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.

Main|Search|PHGKB




Last Posted: Feb 22, 2018

---

• Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?  
  Hughes Dyfrig A et al. Clinical pharmacology and therapeutics 2018 Feb
• Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.  
  Dinh Tuan A et al. Cancer prevention research (Philadelphia, Pa.) 2011 Jan 4(1) 9-22
• Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.  
  Shen Chan et al. Oncotarget 2016 Nov 7(44) 71686-71695
• Screening for Lynch syndrome: it is time to shift the focus.  
  Kidambi Trilokesh D et al. Digestive diseases and sciences 2015 Feb 60(2) 586-7
• Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.  
  Ladabaum Uri et al. Annals of internal medicine 2011 Jul 155(2) 69-79
• The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.  
  Mvundura Mercy et al. Genetics in medicine : official journal of the American College of Medical Genetics 2010 Feb 12(2) 93-104
• Willingness to pay for personalised nutrition across Europe.  
  Fischer Arnout R H et al. European journal of public health 2016 Aug 26(4) 640-4
• Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.  
  Cromwell Ian et al. The oncologist 2016 Sep 21(9) 1099-106
• Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers.  
  Chawla Anita et al. Journal of medical economics 2018 Jan 1-21
• Whole Exome Sequencing in Pediatric Neurology Patients: Clinical Implications and Estimated Cost Analysis.  
  Nolan Danielle et al. Journal of child neurology 2016 Jun 31(7) 887-94
• Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review.  
  García-Pérez Lidia et al. The European journal of health economics : HEPAC : health economics in prevention and care 2017 Dec
• Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.  
  Balentine Courtney J et al. Surgery 2018 Jan 163(1) 88-96
• Appropriateness of newborn screening for classic galactosaemia: a systematic review.  
  Varela-Lema L et al. Journal of inherited metabolic disease 2016 Sep 39(5) 633-49
• Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.  
  Monroe Glen R et al. Genetics in medicine : official journal of the American College of Medical Genetics 2016 Sep 18(9) 949-56
• Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network.  
  Modell Vicki et al. Immunologic research 2016 Jun 64(3) 736-53
• [Implementation and Evaluation of Genetic Testing Seminars about Lifestyle-related Disease Prevention in Pharmacy Insurance-The Need for Cooperation between the Pharmacy and the University in Genetic Testing].  
  Ikeda Kayo et al. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2017 137(12) 1517-1531

more